Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.

These ceramides were also elevated compared to patients receiving other treatment regimens or no treatment, but did not reach statistical significance in all cases.

also in 111,027 other papers

Whereas this observation failed to reach significance on a single trial level, pooled data from several clinical trials clearly showed that IFN-β increased the rate of depression from 8% in the placebo-treated group to 5–18% in patients treated with 22–44 μg IFN-β via different administration routes ( p = 0.017) ( Patten et al., 2005 ).

also in 4,113 other papers